Medical control of intraocular pressure after phacoemulsification

J Cataract Refract Surg. 2005 Mar;31(3):484-8. doi: 10.1016/j.jcrs.2004.07.024.

Abstract

Purpose: To compare the effectiveness of oral acetazolamide, topical brinzolamide 1%, and no ocular hypotensive medication after phacoemulsification.

Setting: Adnan Menderes University Department of Ophthalmology, Aydin, Turkey.

Methods: This prospective randomized double-blind study comprised 60 eyes of 52 patients having phacoemulsification under topical anesthesia. There were no intraoperative complications. Eyes were randomized to receive oral acetazolamide 500 mg 1 hour preoperatively followed by 250 mg acetazolamide every 6 hours, 1 drop of brinzolamide 1% every 12 hours starting immediately after speculum removal, or no ocular hypotensive medication. Intraocular pressure (IOP) was measured using a Perkins tonometer preoperatively and 4 to 6 hours and 18 to 24 hours postoperatively.

Results: The preoperative IOP was not significantly different between the 3 groups. Four to 6 hours postoperatively, the acetazolamide group (P=.002) and brinzolamide group (P=.001) had significantly lower IOP than the control group. The same trend was observed at 18 to 24 hours in the brinzolamide group (P=.001) but not the acetazolamide group (P=.018). The IOP levels were not significantly different between the acetazolamide group and brinzolamide group at any postoperative time point. No eye receiving medication and 2 eyes (10%) in the control group had an IOP of 30 mm Hg or higher 4 to 6 hours postoperatively. Compared with preoperatively, an IOP increase of more than 5 mm Hg was seen at 4 to 6 hours in 3 eyes (15%), 2 eyes (10%), and 14 eyes (70%) in the acetazolamide, brinzolamide, and control group, respectively.

Conclusion: Brinzolamide was as effective as acetazolamide in preventing IOP elevation 4 to 6 hours after phacoemulsification and more effective than acetazolamide at 18 to 24 hours.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acetazolamide
  • Administration, Oral
  • Administration, Topical
  • Adult
  • Aged
  • Aged, 80 and over
  • Carbonic Anhydrase Inhibitors / administration & dosage
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Male
  • Middle Aged
  • Phacoemulsification*
  • Postoperative Complications / prevention & control*
  • Prospective Studies
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use*
  • Thiazines / administration & dosage
  • Thiazines / therapeutic use*
  • Time Factors
  • Tonometry, Ocular

Substances

  • Carbonic Anhydrase Inhibitors
  • Sulfonamides
  • Thiazines
  • brinzolamide
  • Acetazolamide